The two articles written by Dr. Katsuhiko Ito of Hokkaido Venture Capital, Inc., to the September 22, 2008 issue of the NIKKEI BIOTECH (Nikkei Biotechnology & Business) were ranked at the top and the second in the number of viewers for its online version called NIKKEI BIOTECH ON-LINE.

Dr. Ito writes a series of articles under "Research on Product Pipelines" monthly to NIKKEI BIOTECH, in addition to his contribution, the "Research on Product Pipelines in Pharmaceutical Industry" in the Nikkei Biotechnology & Business Almanac.

Hokkaido Venture Capital, Inc. invests, and assists in the development of technology-based ventures, after going through the process of precise technical evaluation from the perspective of technical experts while giving full attention to the trends of the market and the major players in the industry. Also HVC Group provides advices on business and partnership strategies for technology-based ventures and also provides consultation services for large corporations who seek technology transfer from venture companies.

-Related Information-
Link to the homepage of the website for NIKKEI BIOTECH ON-LINE is here. (in Japanese)

-Related Articles in the Past-
One of the HVC and HVC-GI's portfolio companies in US, Tacere Therapeutics, enters collaboration and license agreement with Pfizer to develop and commercialize RNAi Hepatitis C drug. (Jan. 08, 2008)
Gene Techno Science Co., Ltd., one of the Hokkaido VC's portfolio companies, announced a licensing agreement with Kaken Pharmaceutical Co., Ltd. (Jul. 04, 2007)